NuTriaRX CreamPak

Manufacturer
Nucare Pharmaceuticals, Inc. | NuCare Pharmaceuticals,Inc.
Effective date
2018-11-06
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:26:44

Label at a glance#

ProductNuTriaRX CreamPak
Active ingredientDIMETHICONE, TRIAMCINOLONE ACETONIDE
Label structure21 sections

Indications and uses

For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin

Dosage and administration

Cleanse skin with THERA TM Moisturizing Body Cleanser or THERA TM Foaming Body Cleanser Apply cream liberally until entire area is covered Apply as needed

Storage and handling

Protect from freezing. Avoid excessive heat.

Label contents#

Full prescribing information#

Active ingredient

OTC - ACTIVE INGREDIENT SECTION

Dimethicone 5.0%

Purpose

OTC - PURPOSE SECTION

Skin Protectant

Keep out of reach of children

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

If swallowed, get medical help or contact a Poison Control Center right away.

Uses

INDICATIONS & USAGE SECTION


  • For the treatment and/or prevention of diaper rash
  • Temporarily protects and helps relieve chapped or cracked skin

Warnings

WARNINGS SECTION

For external use only


Do not use on

OTC - DO NOT USE SECTION

  • deep or puncture wounds
  • animal bites
  • serious burns

When using this product

OTC - WHEN USING SECTION

  • do not get into eyes

Stop use and ask a doctor if

OTC - STOP USE SECTION

  • condition worsens
  • symptoms last more than 7 days or clear up and occur again within a few days

Directions

DOSAGE & ADMINISTRATION SECTION

  • Cleanse skin with THERA TM Moisturizing Body Cleanser or THERA TM Foaming Body Cleanser
  • Apply cream liberally until entire area is covered
  • Apply as needed

Other information

STORAGE AND HANDLING SECTION

  • Protect from freezing. Avoid excessive heat.

Inactive ingredients

INACTIVE INGREDIENT SECTION

Aleurites Moluccana Seed Oil, Aloe Barbadensis (Aloe Vera) Lead Juice, SAFFLEX TM (Consisting of: Calcium Pantothenate (Vitamin B 5), Maltodextrin, Niacinamide (Vitamin B 3), Pyridoxine HCl (Vitamin B 6), Silica, Sodium Ascorbyl Phosphate (Vitamin C), Sodium Starch Octenylsuccinate, Tocopheryl Acetate (Vitamin E)), Bisabolol, Butylene Glycol, Caprylyl Glycol, Carthamus Tinctorius (Safflower) Oleosomes, Carthamus Tintorius (Safflower) Seed Oil, Cetyl Alcohol, Chlorphenesin, Dimethicone Crosspolymer, Disodium EDTA, Glycerin, Glyceryl Stearate, Lavender Ylang Fragrance, PEG-100 Stearate, Pentaery Tetra-di-t-Butyl Hydroxyhydrocinnamate, Phenoxyethanol, Purified Water, Sodium Hyaluronate, Stearic Acid, Triethanolamine, Zingiber (Ginger) Root Extract.

DESCRIPTION

DESCRIPTION SECTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1, 4-diene-3, 20-dione, 9-flouro-11, 21-dihydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-(11ß16a). Its structural formula is:


Triamcinolone Acetonide StructureTriamcinolone Acetonide Structure

Each gram of Triamcinolone Acetonide Cream USP, 0.025 % contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

Each gram of Triamcinolone Acetonide Cream USP, 0.1 % contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

Each gram of Triamcinolone Acetonide Cream USP, 0.5 % contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION)

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteriods are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS & USAGE

INDICATIONS & USAGE SECTION

Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Triamcinolone acetonide cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

PRECAUTIONS SECTION

GENERAL PRECAUTIONS

GENERAL PRECAUTIONS SECTION

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric Use).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

INFORMATION FOR PATIENTS

INFORMATION FOR PATIENTS SECTION

Patients using topical corticosteroids should receive the following information and instructions.

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

LABORATORY TESTS

LABORATORY TESTS SECTION

The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

PREGNANCY CATEGORY C

PREGNANCY SECTION

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are not adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

NURSING MOTHERS

NURSING MOTHERS SECTION

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

PEDIATRIC USE

PEDIATRIC USE SECTION

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic- pituitary-adrenal (HPA) axis suppression, Cushings's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning

Itching

Irritation

Dryness

Folliculitis

Hypertrichosis

Acneiform eruptions

Hypopigmentation

Perioral dermatitis

Allergic contact dermatitis

Maceration of the skin

Secondary infection

Skin Atrophy

Striae

Miliaria

OVERDOSAGE

OVERDOSAGE SECTION

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

DOSAGE & ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

HOW SUPPLIED SECTION

Triamcinolone acetonide cream USP 0.1% is supplied in
80 g tube NDC 45802-064-36






Store at 20-25°C (68°-77°F) [see USP Controlled Room Temperature].

Avoid excessive heat. Protect from freezing.



PRINTED IN USA



Manufactured for: Ascend Laboratories, LLC Montvale, NJ 07645

Manufactured by: Crown Laboratories, Inc. Johnson City, TN 37604



P1810.01



Revised: Sept 2015

Silicone Tape

DESCRIPTION SECTION

Silicone Tape

Uses

• To be applied to wounds or scars as a protective silicone barrier.

• As a dressing for abrasions, surgical wounds, donor sites, lacerations, ulcers, skin tears, superficial partial thickness burns, venous leg ulcers.

• As a dressing/securement for IV related uses, pressure ulcers, skin care, and wound care

Precautions

• Do not use if you are allergic to silicone

• Keep out of reach of children

Directions for use

• Apply tape to wound or scar as needed or as directed by your physician. Remove tape, wash area, and apply new tape at least every 24 hours.

Dimethicone PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image of 4 fl oz labelimage of 4 fl oz label

Trimcinolone Acetonide Cream USP PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PDPPDP

NuTriaRX CreamPak PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PDPPDP

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
259090dimethicone 5 % Topical CreamPSN2
1014314triamcinolone acetonide 0.1 % Topical CreamPSN2
259090dimethicone 50 MG/ML Topical CreamSCD2
1014314triamcinolone acetonide 1 MG/ML Topical CreamSCD2
259090dimethicone 5 % Topical CreamSY2
1014314triamcinolone acetonide 0.1 % Topical CreamSY2
1014314triamcinolone acetonide 1 MG per GM Topical CreamSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DIMETHICONE Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
TRIAMCINOLONE ACETONIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d4d7da1a-7fd4-628e-cdae-89e749b1c534Product name720260127
75f7e47b-8736-a182-fc44-22aca8d79689Product name220251211
62986c8d-91f1-b1ba-b5a3-8b54b75bb8c2Product name620250516
59361619-24d9-b610-eca6-5a7f25ed5e03Product name520240909
e42f429b-c4e5-0402-e1c5-730154df4060Product name420240205
38d4de13-64b3-4057-b91c-4b5126962341Product name120220516
089e0644-1ea8-8654-4113-39f960dd57d5Product name320210115
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
5331c9c8-f64b-11e6-ccf1-071c477fcb0bProduct name720190612
9f64e0dc-109c-9660-8e0e-91ec987b3817Product name620171204
dfa879a3-32de-49f0-a7ba-9b9c3e13002fProduct name120171204
8de20f81-8411-4cf1-a8b2-03404ee56d01Product name320171109
5e18e798-5614-cf5c-0185-38b1cb77a093Product name220160822
a5f1a68c-0352-4f34-46a3-9b4eed239ed8Product name220160819
355b2224-0895-7135-83f5-d099a6a82a0aProduct name120140508
55be6b50-8cc0-f0f1-74a1-3416a91193aaProduct name120140508
7a0092d1-1e8c-0d78-4f8d-d95fa15cc3cfProduct name120140508
89b93c13-4be8-69f3-b33b-63e64feffb9bProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70859-047-012021-01-29C16284748780-1ba0f9c33-1976-a910-e053-dadaa90a0b85736c0400-88de-c02e-e053-2a91aa0a2264

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
45802-064-36NuTriaRX CreamPak80 g in 1 TUBECREAM80 g1 mg in 1g2
68599-0203-4NuTriaRX CreamPak118 mL in 1 TUBECREAM118 mL50 mg in 1mL2
70859-047-01NuTriaRX CreamPak1 in 1 KITKIT12

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
45802-064NUTRIARX CREAMPAK (RIAMCINOLONE ACETONIDE, DIMETHICONE) KIT [NUCARE PHARMACEUTICALS, INC.]2Current NDC, Legacy NDC20181107_736c0400-88de-c02e-e053-2a91aa0a2264.zip
68599-0203NUTRIARX CREAMPAK (RIAMCINOLONE ACETONIDE, DIMETHICONE) KIT [NUCARE PHARMACEUTICALS, INC.]2Legacy NDC20181107_736c0400-88de-c02e-e053-2a91aa0a2264.zip
70859-047NUTRIARX CREAMPAK (RIAMCINOLONE ACETONIDE, DIMETHICONE) KIT [NUCARE PHARMACEUTICALS, INC.]2Legacy NDC, 3 package rows20181107_736c0400-88de-c02e-e053-2a91aa0a2264.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70859-047-01EA - Each70859-04716266014-facd-4511-bf69-580394f01f8212018-09-05
45802-064-05GM - Gram45802-0648da11a92-dfb6-4fdd-8ccc-bdcc604a7b7412012-07-24
45802-064-35GM - Gram45802-064fe4e08df-c77c-4353-95c3-91eb2c0ef6f912012-07-24
45802-064-36GM - Gram45802-0646abacc99-e30f-4303-b54a-0d9295784de712012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 36 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70859-04770859-047-01
68599-020368599-0203-4
45802-06445802-064-36

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 37 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 2 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A086413-001TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982
A086413-002TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982
A086413-003TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A086413-001AT
A086413-002AT
A086413-003AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982301d65b070ca…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A086413-001AT184e616aacf4f…
2026-09-14 22:38:342026-08A086413-002AT184e616aacf4f…
2026-09-14 22:38:342026-08A086413-003AT184e616aacf4f…
2026-08-18 06:07:402026-07A086413-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-002AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-003AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A086413-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-002AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-003AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-002AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-003AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A086413-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-002AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-003AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-002AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-003AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-002AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-003AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-002AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-003AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-002AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-003AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-002AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-003AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-002AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-003AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A086413-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-002AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-003AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-001AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-002AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-003AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A086413-001AT1301d65b070ca…

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A088042-001TRIDERMTRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALAT1984-03-19
A088042-002TRIDERMTRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALAT2015-03-25
A088042-003TRIDERMTRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALAT2015-03-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A088042-001AT
A088042-002AT
A088042-003AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-1984e616aacf4f…
2026-09-14 22:38:342026-08A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-2584e616aacf4f…
2026-09-14 22:38:342026-08A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-2584e616aacf4f…
2026-08-18 06:07:402026-07A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19caaa826d4ba7…
2026-08-18 06:07:402026-07A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25caaa826d4ba7…
2026-08-18 06:07:402026-07A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19011fe1cb6892…
2026-02-19 14:30 UTC2026-02A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-1931067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-196a471c1ec25d…
2025-08-23 18:47 UTC2025-08A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-1903ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-2503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-192680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-252680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-252680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-195bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-255bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-255bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19d06236e962d9…
2024-10-29 15:01 UTC2024-10A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-25d06236e962d9…
2024-10-29 15:01 UTC2024-10A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-25d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-1979d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-002TRIDERM0.025%CREAM / TOPICALAT2015-03-2579d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-003TRIDERM0.5%CREAM / TOPICALAT2015-03-2579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A088042-001TRIDERM0.1%CREAM / TOPICALAT1984-03-19301d65b070ca…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A088042-001AT184e616aacf4f…
2026-09-14 22:38:342026-08A088042-002AT184e616aacf4f…
2026-09-14 22:38:342026-08A088042-003AT184e616aacf4f…
2026-08-18 06:07:402026-07A088042-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A088042-002AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A088042-003AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A088042-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A088042-002AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A088042-003AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-002AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A088042-003AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A088042-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A088042-002AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A088042-003AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-002AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A088042-003AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-002AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A088042-003AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-002AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A088042-003AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-002AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A088042-003AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-002AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A088042-003AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-002AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A088042-003AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A088042-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A088042-002AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A088042-003AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-001AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-002AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A088042-003AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A088042-001AT1301d65b070ca…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Triamcinolone AcetonideTRIAMCINOLONE ACETONIDEPadagis Israel Pharmaceuticals Ltd5d2fe6c2-3856-47f6-843f-077b2e1080a02024-12-31Adverse reactionsExact identifier
ndc (package): 45802-064-36
ndc (product): 45802-064
ndc11 (package): 45802006436
ScarzenTRIAMCINOLONE ACETONIDE, DIMETHICONEVillage Pharma LLC4777b129-5f7e-49af-9cf7-65158fdf43482024-11-01Warnings, Adverse reactionsExact identifier
ndc (package): 45802-064-36
ndc11 (package): 45802006436
7a0492a6-87d1-76d6-e053-2a91aa0ad61b736c0400-88de-c02e-e053-2a91aa0a22642018-11-06Warnings, Adverse reactionsExact identifier
spl id: 7a0492a6-87d1-76d6-e053-2a91aa0ad61b
spl set id: 736c0400-88de-c02e-e053-2a91aa0a2264

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.